$ADMA - Taking into account the latest results, the latest consensus from ADMA Biologics’s six analysts is for revenues of US$50m in 2020, which would reflect a sizeable 132% improvement in sales compared to the last 12 months. - . There are some variant perceptions on ADMA Biologics, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$10.00 per share. This shows there is still quite a bit of diversity in estimates, but analysts don’t appear to be totally split on the stock as though it might be a success or failure situation. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 17% per year. It seems obvious that, while the growth outlook is brighter than the recent past, analysts also expect ADMA Biologics to grow faster than the wider market. simplywall.st/stocks/us/pha...
  • 12
  • 13